Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 233-238

  Millar, John S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Foam cell; Inflammation; Peroxisome proliferator activated receptor; Type 2 diabetes; VLDL

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ALEGLITAZAR; FENOFIBRATE; MBX 8025; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

ADIPOCYTE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; INTESTINE CELL; MACROPHAGE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ADIPOCYTES; CARDIOVASCULAR DISEASES; ENTEROCYTES; FENOFIBRATE; GENE EXPRESSION REGULATION; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPOPROTEINS; MACROPHAGES; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; RISK; T-LYMPHOCYTES, REGULATORY; THIAZOLIDINEDIONES;

EID: 84880133260     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283613a7d     Document Type: Review

References (26)

1. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375:1875-1884.
2. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
3. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
4. Yew T, Toh SA, Millar JS. Selective peroxisome proliferator-activated receptor-gamma modulation to reduce cardiovascular risk in patients with insulin resistance. Recent Pat Cardiovasc Drug Discov 2012; 7:33-41.
5. Schafer HL, Linz W, Falk E, et al. AVE8134, a novel potent PPARalpha agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta Pharmacol Sin 2012; 33:82-90.
6. Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipo-protein metabolism in humans. Atherosclerosis 2010; 210:35-40.
7. Colin S, Briand O, Touche V, et al. Activation of intestinal peroxisome proliferator-activated receptor-alpha increases high-density lipoprotein production. Eur Heart J 2012. [Epub ahead of print]. doi: 10.1093/eurheartj/ ehs227.
8. Reyes-Soffer G, Ngai CI, Lovato L, et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD Lipid Trial. Diabetes Care 2013;36:422-428.
9. Chan DC, Wong AT, Yamashita S, Watts GF. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis 2012; 221:484-489.
10. Kuang YL, Paulson KE, Lichtenstein AH, Lamon-Fava S. Regulation of the expression of key genes involved in HDL metabolism by unsaturated fatty acids. Br J Nutr 2012; 108:1351-1359.
11. Ogata M, Tsujita M, Hossain MA, et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis 2009; 205:413-419.
12. Ducheix S, Podechard N, Lasserre F, et al. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARalpha. Biochimie 2013; 95:556-567.
13. Duan Y, Chen Y, Hu W, et al. Peroxisome Proliferator-activated receptor gamma activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem 2012; 287:23667-23677.
14. Shao D, Rangwala SM, Bailey ST, et al. Interdomain communication regulating ligand binding by PPAR-gamma. Nature 1998; 396:377-380. (Pubitemid 28557399)
15. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005; 115:1323-1332. (Pubitemid 40629052)
16. Brackenridge AL, Jackson N, Jefferson W, et al. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabet Med 2009; 26:532-539.
17. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72:219-246.
18. Cipolletta D, Feuerer M, Li A, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012; 486:549-553.
19. Matsubara T, Mita A, Minami K, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 2012; 15:38-50.
20. Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011; 332:478-484.
21. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113:159-170. (Pubitemid 36514968)
22. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001; 98:5306-5311. (Pubitemid 32397124)
23. Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol 2012; 32:2289-2294.
24. Iwaisako K, Haimerl M, Paik YH, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci U S A 2012; 109:E1369-1376.
25. Choi YJ, Roberts BK, Wang X, et al. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 2012; 220:470-476.
26. Bojic LA, Sawyez CG, Telford DE, et al. Activation of peroxisome proliferator-activated receptor delta inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein. Arterios-cler Thromb Vasc Biol 2012; 32:2919-2928.